185 related articles for article (PubMed ID: 27682507)
1. Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300.
Crawford TD; Romero FA; Lai KW; Tsui V; Taylor AM; de Leon Boenig G; Noland CL; Murray J; Ly J; Choo EF; Hunsaker TL; Chan EW; Merchant M; Kharbanda S; Gascoigne KE; Kaufman S; Beresini MH; Liao J; Liu W; Chen KX; Chen Z; Conery AR; Côté A; Jayaram H; Jiang Y; Kiefer JR; Kleinheinz T; Li Y; Maher J; Pardo E; Poy F; Spillane KL; Wang F; Wang J; Wei X; Xu Z; Xu Z; Yen I; Zawadzke L; Zhu X; Bellon S; Cummings R; Cochran AG; Albrecht BK; Magnuson S
J Med Chem; 2016 Dec; 59(23):10549-10563. PubMed ID: 27682507
[TBL] [Abstract][Full Text] [Related]
2. GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP).
Romero FA; Murray J; Lai KW; Tsui V; Albrecht BK; An L; Beresini MH; de Leon Boenig G; Bronner SM; Chan EW; Chen KX; Chen Z; Choo EF; Clagg K; Clark K; Crawford TD; Cyr P; de Almeida Nagata D; Gascoigne KE; Grogan JL; Hatzivassiliou G; Huang W; Hunsaker TL; Kaufman S; Koenig SG; Li R; Li Y; Liang X; Liao J; Liu W; Ly J; Maher J; Masui C; Merchant M; Ran Y; Taylor AM; Wai J; Wang F; Wei X; Yu D; Zhu BY; Zhu X; Magnuson S
J Med Chem; 2017 Nov; 60(22):9162-9183. PubMed ID: 28892380
[TBL] [Abstract][Full Text] [Related]
3. Structure-based drug optimization and biological evaluation of tetrahydroquinolin derivatives as selective and potent CBP bromodomain inhibitors.
Bi X; Chen Y; Sun Z; Lu W; Xu P; Lu T; Ding H; Zhang N; Jiang H; Chen K; Zhou B; Luo C
Bioorg Med Chem Lett; 2020 Nov; 30(22):127480. PubMed ID: 32882416
[TBL] [Abstract][Full Text] [Related]
4. Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.
Xiang Q; Wang C; Zhang Y; Xue X; Song M; Zhang C; Li C; Wu C; Li K; Hui X; Zhou Y; Smaill JB; Patterson AV; Wu D; Ding K; Xu Y
Eur J Med Chem; 2018 Mar; 147():238-252. PubMed ID: 29448139
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong
Hu J; Xu H; Wu T; Zhang C; Shen H; Dong R; Hu Q; Xiang Q; Chai S; Luo G; Chen X; Huang Y; Zhao X; Peng C; Wu X; Lin B; Zhang Y; Xu Y
J Med Chem; 2024 May; 67(9):6952-6986. PubMed ID: 38649304
[TBL] [Abstract][Full Text] [Related]
6. Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
Xiang W; Wang Q; Ran K; Ren J; Shi Y; Yu L
Bioorg Chem; 2021 Oct; 115():105238. PubMed ID: 34390970
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening.
Zhang FC; Sun ZY; Liao LP; Zuo Y; Zhang D; Wang J; Chen YT; Xiao SH; Jiang H; Lu T; Xu P; Yue LY; Du DH; Zhang H; Liu CP; Luo C
Acta Pharmacol Sin; 2020 Feb; 41(2):286-292. PubMed ID: 31253937
[TBL] [Abstract][Full Text] [Related]
8. Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.
Li J; Zou W; Yu K; Liu B; Liang W; Wang L; Lu Y; Jiang Z; Wang A; Zhu J
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):903-913. PubMed ID: 33820450
[TBL] [Abstract][Full Text] [Related]
9. Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
Zhao L; Wang Y; Cao D; Chen T; Wang Q; Li Y; Xu Y; Zhang N; Wang X; Chen D; Chen L; Chen YL; Xia G; Shi Z; Liu YC; Lin Y; Miao Z; Shen J; Xiong B
J Med Chem; 2015 Feb; 58(3):1281-97. PubMed ID: 25559428
[TBL] [Abstract][Full Text] [Related]
10. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.
Martin LJ; Koegl M; Bader G; Cockcroft XL; Fedorov O; Fiegen D; Gerstberger T; Hofmann MH; Hohmann AF; Kessler D; Knapp S; Knesl P; Kornigg S; Müller S; Nar H; Rogers C; Rumpel K; Schaaf O; Steurer S; Tallant C; Vakoc CR; Zeeb M; Zoephel A; Pearson M; Boehmelt G; McConnell D
J Med Chem; 2016 May; 59(10):4462-75. PubMed ID: 26914985
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of novel 2'-hydroxy group substituted 2-pyridone derivatives as anticancer agents.
Lv Z; Zhang Y; Zhang M; Chen H; Sun Z; Geng D; Niu C; Li K
Eur J Med Chem; 2013 Sep; 67():447-53. PubMed ID: 23920246
[TBL] [Abstract][Full Text] [Related]
13. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.
Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y
J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of new RNF126-based p300/CBP degraders.
Lei YH; Tang Q; Ni Y; Li CH; Luo P; Huang K; Chen X; Zhu YX; Wang NY
Bioorg Chem; 2024 Jul; 148():107427. PubMed ID: 38728911
[TBL] [Abstract][Full Text] [Related]
16. Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.
Zou LJ; Xiang QP; Xue XQ; Zhang C; Li CC; Wang C; Li Q; Wang R; Wu S; Zhou YL; Zhang Y; Xu Y
Acta Pharmacol Sin; 2019 Nov; 40(11):1436-1447. PubMed ID: 31097763
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of tetrahydroquinolin derivatives as potent inhibitors of CBP bromodomain.
Chen Y; Bi X; Zhang F; Sun Z; Xu P; Jiang H; Lu W; Lu T; Ding H; Zhang N; Jiang H; Chen K; Zhou B; Luo C
Bioorg Chem; 2020 Aug; 101():103991. PubMed ID: 32559581
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300.
Lai KW; Romero FA; Tsui V; Beresini MH; de Leon Boenig G; Bronner SM; Chen K; Chen Z; Choo EF; Crawford TD; Cyr P; Kaufman S; Li Y; Liao J; Liu W; Ly J; Murray J; Shen W; Wai J; Wang F; Zhu C; Zhu X; Magnuson S
Bioorg Med Chem Lett; 2018 Jan; 28(1):15-23. PubMed ID: 29169673
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia.
Wu T; Hu J; Zhao X; Zhang C; Dong R; Hu Q; Xu H; Shen H; Zhang X; Zhang Y; Lin B; Wu X; Xiang Q; Xu Y
J Med Chem; 2024 Jun; 67(11):9194-9213. PubMed ID: 38829718
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative and pro-apoptotic activities of 2'- and 4'-aminochalcones against tumor canine cells.
Santos MB; Pinhanelli VC; Garcia MAR; Silva G; Baek SJ; França SC; Fachin AL; Marins M; Regasini LO
Eur J Med Chem; 2017 Sep; 138():884-889. PubMed ID: 28738308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]